-+ 0.00%
-+ 0.00%
-+ 0.00%

DroneShield Stock And Two Australian Penny Picks Backed By Strong Balance Sheets

Simply Wall St·07/12/2026 03:36:36
语音播报

Penny stocks can look risky when inflation stories, energy prices and interest rate debates dominate the headlines, but a Financially Fit Penny Stocks screener offers a different angle. By focusing on companies trading below 5 with relatively solid balance sheets, this theme seeks to keep attention on financial health rather than speculation. In a world where sovereign yields, labour data and oil moves keep shifting, that filter can help you stay disciplined. In this article, three of the stocks from the Financially Fit Penny Stocks screener will be highlighted to show how this approach can be applied in practice.

DroneShield (ASX:DRO)

Overview: DroneShield is an Australian defence technology company that develops and sells counter-drone hardware and software, helping defence forces, security agencies and critical infrastructure operators detect, track and disable hostile or unauthorised drones across global markets.

Operations: DroneShield generates essentially all of its A$216.8 million of revenue from Aerospace & Defense activities, with A$194.99 million from Australia and the rest of the world and A$29.73 million from the USA, partly offset by A$8.17 million of eliminations.

Market Cap: A$2.1b

DroneShield provides direct exposure to the fast-emerging counter-drone defence category, where activity appears to be shifting from one-off contract wins to more repeat procurement from large institutions such as NATO and US defence channels. Available forecasts indicate expectations of revenue and earnings growth, and while current Return on Equity is low, expectations of higher margins suggest the business model is still maturing. The appointment of senior defence figures such as retired Rear Admiral Lee Goddard indicates deeper ties into procurement circles. Investors also need to weigh risks such as funding that relies on external borrowing and an ASIC investigation into past disclosures. For anyone following the Financially Fit Penny Stocks theme, this mix of growth potential and real-world adoption may be of interest.

DroneShield’s shift toward repeat defence contracts and higher margin expectations is getting attention. The real question is how far this could go if current forecasts hold. Get the full picture with the analyst forecasts for DroneShield

ASX:DRO Earnings & Revenue Growth as at Jul 2026
ASX:DRO Earnings & Revenue Growth as at Jul 2026

Sigma Healthcare (ASX:SIG)

Overview: Sigma Healthcare is an Australian pharmaceutical wholesaler and distributor that also runs and supports a large network of franchised retail pharmacies, including Chemist Warehouse, Amcal and Discount Drug Stores, as well as offering online sales and logistics services for drug manufacturers and other health suppliers.

Operations: Sigma Healthcare generates A$9.5b of revenue from Healthcare activities, with A$9.2b from Australia and A$389.8m from international markets.

Market Cap: A$32.4b

Investors looking at Sigma Healthcare are weighing a large, established Australian pharmacy and wholesale platform with strong historical earnings growth against a richer P/E multiple and some governance questions. Earnings have grown at an average 30.8% per year over the past 5 years and are forecast to keep rising, with revenue also expected to grow faster than the broader Australian market. However, margins have narrowed and Return on Equity sits at 12.2%. The company recently pulled back from a potential A$10b Boots acquisition, which may indicate capital discipline and a renewed focus on its core Australian operations. The tension between this growth profile, funding risk from reliance on external borrowing and a board that has seen rapid change is a key consideration for investors assessing Sigma Healthcare.

Sigma Healthcare’s earnings growth record, tighter margins and richer P/E raise a simple question: is the market pricing the full story yet or missing something important in the analyst forecasts for Sigma Healthcare

ASX:SIG Earnings & Revenue Growth as at Jul 2026
ASX:SIG Earnings & Revenue Growth as at Jul 2026

Stanmore Resources (ASX:SMR)

Overview: Stanmore Resources is an Australian coal producer focused on mining, processing and selling metallurgical coal used in steelmaking, with a large portfolio of exploration tenements across Queensland’s Bowen and Surat basins and backing from major shareholder Golden Investments.

Operations: Stanmore Resources generates about $1.9b of revenue from producing and selling metallurgical and thermal coal, primarily to customers in Asia, Europe and South America.

Market Cap: A$2.1b

Stanmore Resources stands out in the Financially Fit Penny Stocks screener as a coal producer where the real story sits at the crossroads of operational efficiency and a potential step change in scale. Analysts expect earnings to improve even though revenue is forecast to soften slightly, which points to cost discipline, automation and higher margin expectations doing more of the heavy lifting. The company is also in the mix for Anglo American’s Queensland coal portfolio, a deal that could require up to $1.5b of new equity and materially reshape its asset base. Set against this are real risks, from volatile metallurgical coal prices and Queensland weather to regulatory and funding pressures, which makes Stanmore a stock where the upside and the tripwires both deserve close attention.

Stanmore Resources could be at an inflection point, with operational discipline and a possible Anglo deal reshaping the story. The real twist sits inside the analysis report for Stanmore Resources

ASX:SMR Earnings & Revenue Growth as at Jul 2026
ASX:SMR Earnings & Revenue Growth as at Jul 2026

The three stocks in this article are only a starting point, with the full screener surfacing 403 more companies in the Financially Fit Penny Stocks screener that show similarly interesting combinations of balance sheet strength and early stage potential. Use Simply Wall St to identify, analyze and filter for the exact catalysts and narratives that matter to you so you can focus on the highest conviction opportunities in this corner of the market.

Take Control of Your Investment Journey

If Sigma Healthcare or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Fresh opportunities can move from quiet to breakout quickly. Once momentum builds, ideal entry points can get caught and start dropping. Scan these curated ideas now to evaluate them at an earlier stage.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.